Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 1
1996 1
2004 1
2005 1
2007 1
2008 3
2009 1
2010 6
2011 4
2012 6
2013 3
2014 4
2015 9
2016 12
2017 5
2018 14
2019 5
2020 6
2021 16
2022 7
2023 13
2024 11
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

116 results

Results by year

Filters applied: . Clear all
Page 1
A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, Romero D, Abdelmalek MF, Anstee QM, Arab JP, Arrese M, Bataller R, Beuers U, Boursier J, Bugianesi E, Byrne CD, Castro Narro GE, Chowdhury A, Cortez-Pinto H, Cryer DR, Cusi K, El-Kassas M, Klein S, Eskridge W, Fan J, Gawrieh S, Guy CD, Harrison SA, Kim SU, Koot BG, Korenjak M, Kowdley KV, Lacaille F, Loomba R, Mitchell-Thain R, Morgan TR, Powell EE, Roden M, Romero-Gómez M, Silva M, Singh SP, Sookoian SC, Spearman CW, Tiniakos D, Valenti L, Vos MB, Wong VW, Xanthakos S, Yilmaz Y, Younossi Z, Hobbs A, Villota-Rivas M, Newsome PN; NAFLD Nomenclature consensus group. Rinella ME, et al. Hepatology. 2023 Dec 1;78(6):1966-1986. doi: 10.1097/HEP.0000000000000520. Epub 2023 Jun 24. Hepatology. 2023. PMID: 37363821 Free PMC article.
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, Alkhouri N, Bansal MB, Baum S, Neuschwander-Tetri BA, Taub R, Moussa SE. Harrison SA, et al. Among authors: moylan ca. Lancet. 2019 Nov 30;394(10213):2012-2024. doi: 10.1016/S0140-6736(19)32517-6. Epub 2019 Nov 11. Lancet. 2019. PMID: 31727409 Clinical Trial.
REPLY.
Wegermann K, Suzuki A, Mavis AM, Abdelmalek MF, Diehl AM, Moylan CA. Wegermann K, et al. Among authors: moylan ca. Hepatology. 2021 Apr;73(4):1625. doi: 10.1002/hep.31593. Hepatology. 2021. PMID: 33040372 No abstract available.
The Liver Cirrhosis Network Cohort Study: Cirrhosis Definition, Study Population, and Endpoints.
Tapper EB, Goldberg D, Parikh ND, Terrault NA, Welch N, Sharpton S, Hameed B, Khalili M, Stolz A, Verna EC, Brown RS Jr, Sanyal AJ, VanWagner L, Ladner DP, Moylan CA, Diehl AM, Jones PD, Loomba R, Dasarathy S, Simonetto DA, Shah VH, Bajaj JS; LCN Study Group. Tapper EB, et al. Among authors: moylan ca. Am J Gastroenterol. 2025 Mar 1;120(3):570-575. doi: 10.14309/ajg.0000000000002953. Epub 2024 Jul 17. Am J Gastroenterol. 2025. PMID: 39018024
Osteopontin Promotes Cholangiocyte Secretion of Chemokines to Support Macrophage Recruitment and Fibrosis in MASH.
Coombes JD, Manka PP, Swiderska-Syn M, Vannan DT, Riva A, Claridge LC, Moylan C, Suzuki A, Briones-Orta MA, Younis R, Kitamura N, Sydor S, Bittencourt S, Mi Z, Kuo PC, Diehl AM, van Grunsven LA, Chokshi S, Canbay A, Abdelmalek MF, Aspichueta P, Papa S, Eksteen B, Syn WK. Coombes JD, et al. Among authors: moylan c. Liver Int. 2025 Apr;45(4):e16131. doi: 10.1111/liv.16131. Epub 2024 Oct 18. Liver Int. 2025. PMID: 39422353 Free article.
Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
Bowlus CL, Eksteen B, Cheung AC, Thorburn D, Moylan CA, Pockros PJ, Forman LM, Dorenbaum A, Hirschfield GM, Kennedy C, Jaecklin T, McKibben A, Chien E, Baek M, Vig P, Levy C. Bowlus CL, et al. Among authors: moylan ca. Hepatol Commun. 2023 May 15;7(6):e0153. doi: 10.1097/HC9.0000000000000153. eCollection 2023 Jun 1. Hepatol Commun. 2023. PMID: 37184523 Free PMC article.
Fatty Liver Disease: Enter the Metabolic Era.
Wegermann K, Moylan C, Naggie S. Wegermann K, et al. Among authors: moylan c. Curr HIV/AIDS Rep. 2023 Dec;20(6):405-418. doi: 10.1007/s11904-023-00669-7. Epub 2023 Oct 26. Curr HIV/AIDS Rep. 2023. PMID: 37882965 Review.
Updates in nonalcoholic fatty liver disease.
Wungjiranirun M, Wong N, Jou J, Moylan CA. Wungjiranirun M, et al. Among authors: moylan ca. Clin Liver Dis (Hoboken). 2023 Nov 17;22(5):157-161. doi: 10.1097/CLD.0000000000000085. eCollection 2023 Nov. Clin Liver Dis (Hoboken). 2023. PMID: 38026121 Free PMC article. No abstract available.
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data.
Ng WH, Yeo YH, Kim H, Seki E, Rees J, Ma KS, Moylan CA, Rodriquez LM, Abdelmalek M, Villanueva A, Noureddin M, Yang JD. Ng WH, et al. Among authors: moylan ca. Hepatology. 2025 Apr 2. doi: 10.1097/HEP.0000000000001333. Online ahead of print. Hepatology. 2025. PMID: 40178454
116 results